New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2012
07:19 EDTVRXValeant price target raised to $75 from $64 at Jefferies
Jefferies says Valeant's 2012 guidance was even better than its optimistic forecasts, and finds the company's goal of being a top 15 Pharma company by the end of 2013 intriguing. The firm says the goal would equate to a $160 per share valuation. Jefferies raised its price target for Valeant shares and keeps a Buy rating on the stock.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
06:19 EDTVRXPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use